Drug Trial Radar · NCT07052162
Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 20, 2025
Primary completion
Mar 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- Curtin UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Papua New Guinea Institute of Medical Research; The University of Western Australia
- First posted
- Jul 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide. It accounts for half of all malaria cases outside Africa, with an estimated 14.3 million clinical vivax malaria cases reported annually, contributing to an annual cost of US$359 million. Children are most vulnerable to infection, with P. vivax prevalence peaking between 2 to 6 years of age. In Papua New Guinea (PNG), there are \>1.5 million suspected P. vivax cases annually, and while P. falciparum infections are the most prevalent, P. vivax transmission is the most intense in the world. P. vivax in PNG provides a unique epidemiological setting in which to assess innovative treatments in children. The complex biology of P. vivax represents a challenge for malaria control and chemotherapy, especially dormant liver-stage parasites (hypnozoites) which can reactivate (relapse) and cause disease at a time remote from the primary infection. Hypnozoite relapse is the primary cause of vivax malaria in endemic regions and is resistant to most antimalarial drugs. Identifying effective treatments for radical cure, the complete elimination of parasites (both blood- and liver-stage), is therefore a priority. The World Health Organization (WHO) recommends a 14-day radical cure regimen for uncomplicated vivax malaria; comprised of blood stage treatment (chloroquine or artemisinin combination therapy (ACT)) and 14 days of the 8-aminoquinoline drug primaquine (PQ; 0.25-0.5 mg/kg/day) for liver-stage cure. More recently, the 8-aminoquinoline tafenoquine has garnered interest as an alternative radical cure agent to primaquine. However, there is limited data on the pharmacokinetics, tolerability and radical cure efficacy of tafenoquine in children. The overall aim of the study is to characterise the pharmacokinetic profile of tafenoquine (and primary metabolite) in Papua New Guinean children.
Conditions
- Pharmacokinetics of Tafenoquine
Interventions
Single dose tafenoquine (10 mg/kg) given with waterDrug
Participants will receive single-dose TQ as 10 mg/kg taken with water and a low-fat meal (3 plain cracker biscuits; 2% fat). Food (low-fat meal) is taken with both regimens to attenuate any gastrointestinal adverse effects that are related to taking TQ on an empty stomach. Combinations of full or half-tablets will be swallowed whole or crushed lightly (tablets) or dissolved in boiled water (if dispersible tablets are available), as directly observed treatment. Children vomiting within the first 30 minutes of treatment will be withdrawn
Single dose tafenoquine (10 mg/kg) given with fatDrug
Single-dose TQ as 10 mg/kg taken with 250 mL chocolate flavoured milk (9% fat) and a low-fat meal (3 plain cracker biscuits). Food (low-fat meal) is taken with both regimens to attenuate any gastrointestinal adverse effects that are related to taking TQ on an empty stomach. Combinations of full or half-tablets will be swallowed whole or crushed lightly (tablets) or dissolved in boiled water (if dispersible tablets are available), as directly observed treatment. Children vomiting within the first 30 minutes of treatment will be withdrawn
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic: Distribution half-lifeTime frame: 56-days after drug administration
- Pharmacokinetic: Terminal elimination half-lifeTime frame: 56-days after drug administration
- Pharmacokinetic: Absorption half-lifeTime frame: 56-days after drug administration
- Pharmacokinetics: ClearanceTime frame: 56-days after drug administration
- Pharmacokinetics: Volume of distributionTime frame: 56-days after drug administration
- Pharmacokinetics: Maximal concentrationTime frame: 56-days after drug administration
- Pharmacokinetics: Area under concentration-time curveTime frame: 56-days after drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alexishafen Health Centre
Madang, Madang Province, Papua New Guinea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.